Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

Wils P, Altwegg R, Buisson A, Vuitton L, Nancey S, Richard N, Fumery M, Bouguen G, Guillo L, Caron B, Duveau N, Stefanescu C, Pelletier AL, Reenaers C, Gilletta C, Uzzan M, Arab N, Laharie D, Vidon M, Amiot A, Le Berre C, Kirchgesner J, Dewit O, Simon M, Goutorbe F, Vicaut E, Peyrin-Biroulet L, Groupe d‘Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)

Open source

DOI: 10.1093/ecco-jcc/jjaf166
Published: 2025 Sep 28
Container: Journal of Crohn's & colitis
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ecco-jcc/jjaf166,
  title = {Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.},
  author = {Wils P and Altwegg R and Buisson A and Vuitton L and Nancey S and Richard N and Fumery M and Bouguen G and Guillo L and Caron B and Duveau N and Stefanescu C and Pelletier AL and Reenaers C and Gilletta C and Uzzan M and Arab N and Laharie D and Vidon M and Amiot A and Le Berre C and Kirchgesner J and Dewit O and Simon M and Goutorbe F and Vicaut E and Peyrin-Biroulet L and Groupe d‘Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)},
  year = {2025},
  journal = {Journal of Crohn's \& colitis},
  doi = {10.1093/ecco-jcc/jjaf166},
  url = {https://doi.org/10.1093/ecco-jcc/jjaf166}
}

RIS

TY  - JOUR
TI  - Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.
AU  - Wils P
AU  - Altwegg R
AU  - Buisson A
AU  - Vuitton L
AU  - Nancey S
AU  - Richard N
AU  - Fumery M
AU  - Bouguen G
AU  - Guillo L
AU  - Caron B
AU  - Duveau N
AU  - Stefanescu C
AU  - Pelletier AL
AU  - Reenaers C
AU  - Gilletta C
AU  - Uzzan M
AU  - Arab N
AU  - Laharie D
AU  - Vidon M
AU  - Amiot A
AU  - Le Berre C
AU  - Kirchgesner J
AU  - Dewit O
AU  - Simon M
AU  - Goutorbe F
AU  - Vicaut E
AU  - Peyrin-Biroulet L
AU  - Groupe d‘Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
PY  - 2025
JO  - Journal of Crohn's & colitis
DO  - 10.1093/ecco-jcc/jjaf166
UR  - https://doi.org/10.1093/ecco-jcc/jjaf166
ER  -

APA

P, W., R, A., A, B., L, V., S, N., N, R., M, F., G, B., L, G., B, C., N, D., C, S., AL, P., C, R., C, G., M, U., N, A., D, L., M, V., A, A., C, L. B., J, K., O, D., M, S., F, G., E, V., L, P., & (GETAID), G. D. T. D. A. I. D. T. D. (2025). Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.. Journal of Crohn's & colitis. https://doi.org/10.1093/ecco-jcc/jjaf166

Source records

pubmed · retrieved 2026-09-27T13:10:30.078Z